0000000000765380

AUTHOR

Vatche G. Agopian

showing 2 related works from this author

Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patie…

2020

Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Although Milan Criteria (MC) generalized the practice of LT for HCC and improved outcomes, its predictive character has degraded with increasing candidate and oncological heterogeneity. We sought to validate and recalibrate a previously developed, preoperatively calculated, continuous risk score, the Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma (HALTHCC), in an international cohort. From 2002 to 2014, 4,089 patients (both MC in and out [25.2%]) across 16 centers in North America, Europe, and Asia were included. A continuous risk score using pre-…

OncologyMalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatmentInternational CooperationPROGNOSTIC SCORETumor burdengastroenterologyLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCORELiver transplantationMilan criteriaRisk AssessmentLiver diseaseInternal medicinemedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapiesHEPATOCELLULAR CARCINOMARetrospective StudiesOUTCOMEFramingham Risk ScoreHepatologybusiness.industryPoorly differentiatedLiver Neoplasmshepatocelluar cancerMiddle Agedmedicine.diseasePrognosisSettore MED/18Liver TransplantationRISK FACTORSHepatocellular carcinomaCohortlocoregional therapiesFemalebusinessHepatology (Baltimore, Md.)References
researchProduct

Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.

2021

IMPORTANCE: Accurate preoperative prediction of hepatocellular carcinoma (HCC) recurrence after liver transplant is the mainstay of selection tools used by transplant-governing bodies to discern candidacy for patients with HCC. Although progress has been made, few tools incorporate objective measures of tumor biological characteristics, resulting in inclusion of patients with high recurrence rates and exclusion of others who could otherwise be cured. OBJECTIVE: To externally validate the New York/California (NYCA) score, a recently published multi-institutional US HCC selection tool that was the first model incorporating a dynamic α-fetoprotein response (AFP-R) and compare the validated sco…

MaleOncologymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatment030230 surgeryLiver transplantationMilan criteriaRisk AssessmentDisease-Free Survival03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumansCumulative incidenceAgedProportional Hazards ModelsRetrospective StudiesReceiver operating characteristicbusiness.industryLiver NeoplasmsRegression analysisMiddle Agedmedicine.diseaseRegressionLiver TransplantationSurvival RateTransplantationROC Curve030220 oncology & carcinogenesisHepatocellular carcinomaFemaleSurgeryalpha-Fetoproteinsbusiness
researchProduct